We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Pfizer to Buy King Pharmaceuticals

By LabMedica International staff writers
Posted on 25 Oct 2010
Pharmaceutical giant Pfizer (New York, NY, USA) has agreed to buy King Pharmaceuticals (King; Bristol, TN, USA), a small drug maker that sells painkillers, in a US$3.6 billion cash deal aimed at diversifying global sales prior to the 2011 patent expiration of its top-selling product, cholesterol fighter Lipitor.

The purchase is intended to move Pfizer into a roughly $6 billion market in the United States alone for opioids. More...
The market for potent pain medicines is dominated by mostly small or generic drug makers that lack the marketing muscle of Pfizer. The company plans to use salespeople already selling its arthritis drug Celebrex and fibromyalgia treatment Lyrica to promote King's products as well. The companies expect to close the deal by early 2011, subject to regulatory approvals and other closing conditions.

While widely used to relieve serious chronic pain, opiod use has been marred by reports of abuse, including unintentional deaths; King has been working on formulations that deter nonmedical use. Among other products, King sells the morphine drug Embeda, and is in the late stages of developing a treatment called Remoxy based on another ingredient, oxycodone. King also sells the Flector Patch to treat pain stemming from minor sprains and bruises, and the EpiPen for injecting epinephrine to quickly treat severe allergic reactions. In addition, it sells medicinal feed additives that Pfizer executives said would fit into the company's animal-health business.

"The combination of our respective portfolios in this area of unmet medical need is highly complementary and will allow us to offer a fuller spectrum of treatments for patients across the globe who are in need of pain relief and management," said Jeffrey Kindler, chairman and CEO of Pfizer. "In addition, the revenue generated by King's portfolio will further diversify Pfizer's business, while at the same time contributing to steady earnings growth and shareholder value."

"By bringing together King's capabilities in new formulations of pain treatments, designed to discourage common methods of misuse and abuse, with Pfizer's commercial, medical and regulatory expertise, global strength in patient services and reimbursement, and global scale and resources, we believe Pfizer can build on our foundation and take our business to the next level," said Brian Markison, chairman and CEO of King Pharmaceuticals.

Related Links:

Pfizer
King Pharmaceuticals



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Immunoassay Analyzer
Procise DX
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.